Professor Jonathan West was the founding Director of the Australian Innovation Research Centre. Prior to assuming that appointment, he taught for 18 years at the Harvard University Graduate School of Business Administration, where he was Associate Professor, founding Director of the Harvard University Life Sciences Initiative, and from 1998-1999 the Novartis Faculty Research Fellow. He has been Visiting Professor at Hitotsubashi University and the Nomura School of Advanced Management in Tokyo, Japan and Visiting Professor at the University de Paris IX-Dauphine, Sorbonne.
Professor West was Chairman of the Asia Advisory Council of Bunge Ltd, one of the world’s largest agribusiness processing and trading companies, and has served as an advisor to other major corporations and several Governments around the world, including in the life sciences field, DuPont, Roche, Novartis, Syngenta and the J.R. Simplot Company, along with the Governments of Singapore, Japan, Hong Kong and France. He was a member of the Scientific Advisory Board of the Novartis Agricultural Discovery Institute in La Jolla, California. In Australia, he has served on the Prime Minister’s Science, Engineering, Innovation Council’s Working Group on Science and Technology in China and India and in 2006 was ‘Eminent Thinker in Residence’ with the Premier of NSW. Professor West is Non-Executive Chairman of Gowing Bros Limited and Non-Executive Director of Boundary Bend Limited and the Hydration Pharmaceuticals Trust.
Professor West has been a Director of the Company since 7 November 2005 and was appointed Non-Executive Chairman on 18 November 2014. He is a member of the Remuneration and Nomination Committee and Chairman of the Audit and Risk Management Committee.
Wilsons Equity Research has released an updated analysis on Hexima Limited, with a view on the potential for success in phase II. Wilsons maintains its OVERWEIGHT rating and a $0.75 12-month price target. View the full report (pdf)
Hexima CEO, Michael Aldridge, presented at the ShareCafe Hidden Gems Webinar on 29 April 2022 at 12:30pm AEST. Mr Aldridge provided a company overview and discussed its phase II clinical trial, including when the company is expecting results from the trial. This...
Hexima is proud to release its “NailMail” quarterly activities report for the quarter ended 31 March 2022. Achievements for the quarter include: Appointed Mr Philip Rose as Chief Commercial Officer and strengthened the manufacturing team with the appointment of Mr Om...